Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID‐19: Design and rationale for the DARE‐19 study

AIMS: Coronavirus disease 2019 (COVID‐19) is caused by a novel severe acute respiratory syndrome coronavirus 2. It can lead to multiorgan failure, including respiratory and cardiovascular decompensation, and kidney injury, with significant associated morbidity and mortality, particularly in patients...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Diabetes Obes Metab
Main Authors: Kosiborod, Mikhail, Berwanger, Otavio, Koch, Gary G., Martinez, Felipe, Mukhtar, Omar, Verma, Subodh, Chopra, Vijay, Javaheri, Ali, Ambery, Philip, Gasparyan, Samvel B., Buenconsejo, Joan, Sjöström, C. David, Langkilde, Anna Maria, Oscarsson, Jan, Esterline, Russell
פורמט: Artigo
שפה:Inglês
יצא לאור: Blackwell Publishing Ltd 2021
נושאים:
Clinical Trial Design
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC8049025/
https://ncbi.nlm.nih.gov/pubmed/33319454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.14296
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים